Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
5.71
-0.15 (-2.56%)
At close: Feb 18, 2026, 4:00 PM EST
5.72
+0.01 (0.13%)
After-hours: Feb 18, 2026, 7:54 PM EST
Verastem Employees
Verastem had 78 employees as of December 31, 2024. The number of employees increased by 5 or 6.85% compared to the previous year.
Employees
78
Change (1Y)
5
Growth (1Y)
6.85%
Revenue / Employee
$171,526
Profits / Employee
-$3,091,103
Market Cap
440.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | 48 | -87 | -64.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Kyverna Therapeutics | 129 |
| Invivyd | 100 |
| Solid Biosciences | 100 |
| Ocugen | 95 |
| Assembly Biosciences | 73 |
| Lexeo Therapeutics | 61 |
| PepGen | 57 |
| Zura Bio | 30 |
VSTM News
- 16 hours ago - Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire
- 14 days ago - Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 5 weeks ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC - Seeking Alpha
- 7 weeks ago - Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth - Business Wire
- 3 months ago - Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference - Business Wire
- 3 months ago - Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants - Business Wire